Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Next Previous
Drug Profile

Research programme: cancer and infectious diseases vaccines - ISA Pharmaceuticals

Alternative Names: Hepatitis B vaccine - ISA Pharmaceuticals; HPV SLP®-AMPLIVANT™ vaccine; HPV16-peptides-AMPLIVANT-vaccine; ISA 203; ISA-204; MyISA®; Peptide vaccines - ISA Pharmaceuticals; PRAME vaccine; SLP-AMPLIVANT-conjugate-head-and-neck-cancer-vaccine; SLP® vaccines; SLP®-AMPLIVANT™ conjugate vaccines; SLP®-AMPLIVANT™ melanoma vaccine

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ISA Pharmaceuticals
  • Class Cancer vaccines; Conjugate vaccines; Hepatitis B vaccines; Immunotherapies; Peptide vaccines; Tuberculosis vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer; Hepatitis B; Tuberculosis; Viral infections

Most Recent Events

  • 28 May 2025 No recent reports of development identified for preclinical development in Cancer in Netherlands (Parenteral)
  • 31 May 2023 Research programme is still in preclinical phase for Cancer in Netherlands (ISA Pharmaceuticals pipeline; May 2023)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Hepatitis-B in Netherlands

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top